Drugs / SAF312
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04630158 | Apr 2021 → Jun 2023 | chronic pain syndrome | Novartis Pharmaceuticals | Completed | Missed primary |
| Phase 2 | NCT02961062 | Dec 2016 → Jan 2018 | — | Novartis Pharmaceuticals | Completed | Met primary |
| Phase 2 | NCT01598103 | Jan → Sep 2012 | low compliance bladder, overactive bladder | Novartis Pharmaceuticals | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SAF312 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02961062 ↗ |
| Action | Inhibit | “Vanilloid receptor inhibitor” CHEMBL3544953 ↗ |
| Route | Oral | “hard gelatin capsules for oral use” NCT01598103 ↗ |
| Target | TRPV1 | “Vanilloid receptor inhibitor” CHEMBL3544953 ↗ |